ESA use in women with cancer: Consequences of the 2008 FDA clinical alert.

5040 Background: Erythropoietin stimulating agents (ESA) are used clinically as an alternative to blood transfusions in cancer patients suffering from symptoms of anemia. However, more recent rando...